Lumax Auto Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 29, 2025, 9:20 pm

Quick Insight

Lumax Auto Technologies Ltd currently trades at ₹1,259 with a market capitalization of ₹8,564 Cr. The company's P/E ratio stands at 45.7, reflecting a premium valuation compared to the sector average of around 30 in the Indian auto ancillary industry. Notably, Lumax boasts a robust Return on Equity (ROE) of 20.2% and Return on Capital Employed (ROCE) of 19.0%, outperforming many peers. With a healthy Operating Profit Margin (OPM) of 12% and a comfortable Interest Coverage Ratio (ICR) of 6.53x, the company demonstrates operational efficiency and financial stability, appealing to investors.

However, Lumax faces risks due to its high valuation multiples, notably a Price-to-Book Value (P/BV) ratio of 3.93x, indicating an expensive stock relative to its book value. Moreover, the company's heavy reliance on promoters, with 55.98% shareholding, raises concerns about minority shareholder influence. Looking ahead, Lumax's growth prospects hinge on its ability to diversify revenue streams, innovate in a competitive market, and effectively manage working capital to improve its Cash Conversion Cycle (CCC) of 24 days. Investors should closely monitor these factors to gauge the company's future performance accurately.

In conclusion, while Lumax Auto Technologies exhibits solid financial metrics and operational efficiency, investors should remain cautious of its rich valuation and ownership structure. Monitoring the company's strategic initiatives to drive growth and enhance shareholder value will be crucial for making informed investment decisions in the dynamic auto ancillary sector.

Competitors of Lumax Auto Technologies Ltd

All Competitor Stocks of Lumax Auto Technologies Ltd

Quarterly Result

Last Updated: August 20, 2025, 7:40 am

Below is a detailed analysis of the quarterly data for Lumax Auto Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,026.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,133.00 Cr. (Mar 2025) to 1,026.00 Cr., marking a decrease of 107.00 Cr..
• For Expenses, as of Jun 2025, the value is 901.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 976.00 Cr. (Mar 2025) to 901.00 Cr., marking a decrease of 75.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 125.00 Cr.. The value appears to be declining and may need further review. It has decreased from 157.00 Cr. (Mar 2025) to 125.00 Cr., marking a decrease of 32.00 Cr..
• For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 12.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 2.00 Cr..
• For Interest, as of Jun 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 38.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37.00 Cr. (Mar 2025) to 38.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 108.00 Cr. (Mar 2025) to 74.00 Cr., marking a decrease of 34.00 Cr..
• For Tax %, as of Jun 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Mar 2025) to 27.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 54.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2025) to 54.00 Cr., marking a decrease of 26.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 6.08. The value appears to be declining and may need further review. It has decreased from 8.57 (Mar 2025) to 6.08, marking a decrease of 2.49.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:54 pm

Growth

Last Updated: September 5, 2025, 9:55 am

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Lumax Auto Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 26.08. This value is within the healthy range. It has increased from 19.10 (Mar 24) to 26.08, marking an increase of 6.98.
• For Diluted EPS (Rs.), as of Mar 25, the value is 26.08. This value is within the healthy range. It has increased from 19.10 (Mar 24) to 26.08, marking an increase of 6.98.
• For Cash EPS (Rs.), as of Mar 25, the value is 52.49. This value is within the healthy range. It has increased from 41.81 (Mar 24) to 52.49, marking an increase of 10.68.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 137.14. It has decreased from 148.66 (Mar 24) to 137.14, marking a decrease of 11.52.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 137.14. It has decreased from 148.66 (Mar 24) to 137.14, marking a decrease of 11.52.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 533.57. It has increased from 414.00 (Mar 24) to 533.57, marking an increase of 119.57.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 75.68. This value is within the healthy range. It has increased from 60.61 (Mar 24) to 75.68, marking an increase of 15.07.
• For PBIT / Share (Rs.), as of Mar 25, the value is 56.81. This value is within the healthy range. It has increased from 43.29 (Mar 24) to 56.81, marking an increase of 13.52.
• For PBT / Share (Rs.), as of Mar 25, the value is 45.21. This value is within the healthy range. It has increased from 33.27 (Mar 24) to 45.21, marking an increase of 11.94.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 33.62. This value is within the healthy range. It has increased from 24.50 (Mar 24) to 33.62, marking an increase of 9.12.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.08. This value is within the healthy range. It has increased from 19.10 (Mar 24) to 26.08, marking an increase of 6.98.
• For PBDIT Margin (%), as of Mar 25, the value is 14.18. This value is within the healthy range. It has decreased from 14.63 (Mar 24) to 14.18, marking a decrease of 0.45.
• For PBIT Margin (%), as of Mar 25, the value is 10.64. This value is within the healthy range. It has increased from 10.45 (Mar 24) to 10.64, marking an increase of 0.19.
• For PBT Margin (%), as of Mar 25, the value is 8.47. This value is below the healthy minimum of 10. It has increased from 8.03 (Mar 24) to 8.47, marking an increase of 0.44.
• For Net Profit Margin (%), as of Mar 25, the value is 6.30. This value is within the healthy range. It has increased from 5.91 (Mar 24) to 6.30, marking an increase of 0.39.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 8. It has increased from 4.61 (Mar 24) to 4.88, marking an increase of 0.27.
• For Return on Networth / Equity (%), as of Mar 25, the value is 19.01. This value is within the healthy range. It has increased from 16.48 (Mar 24) to 19.01, marking an increase of 2.53.
• For Return on Capital Employeed (%), as of Mar 25, the value is 21.28. This value is within the healthy range. It has increased from 19.82 (Mar 24) to 21.28, marking an increase of 1.46.
• For Return On Assets (%), as of Mar 25, the value is 5.48. This value is within the healthy range. It has increased from 5.00 (Mar 24) to 5.48, marking an increase of 0.48.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.36, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.82. This value is within the healthy range. It has decreased from 0.86 (Mar 24) to 0.82, marking a decrease of 0.04.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.25. It has increased from 1.18 (Mar 24) to 1.25, marking an increase of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 1.12. This value is below the healthy minimum of 1.5. It has decreased from 1.19 (Mar 24) to 1.12, marking a decrease of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.86, marking a decrease of 0.10.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.82. This value exceeds the healthy maximum of 8. It has increased from 7.50 (Mar 24) to 11.82, marking an increase of 4.32.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 21.08. This value is within the healthy range. It has decreased from 23.55 (Mar 24) to 21.08, marking a decrease of 2.47.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 12.23. This value is below the healthy minimum of 20. It has decreased from 12.35 (Mar 24) to 12.23, marking a decrease of 0.12.
• For Earning Retention Ratio (%), as of Mar 25, the value is 78.92. This value exceeds the healthy maximum of 70. It has increased from 76.45 (Mar 24) to 78.92, marking an increase of 2.47.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 87.77. This value exceeds the healthy maximum of 70. It has increased from 87.65 (Mar 24) to 87.77, marking an increase of 0.12.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.53. This value is within the healthy range. It has increased from 6.04 (Mar 24) to 6.53, marking an increase of 0.49.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.90. This value is within the healthy range. It has increased from 3.44 (Mar 24) to 3.90, marking an increase of 0.46.
• For Enterprise Value (Cr.), as of Mar 25, the value is 4,724.36. It has increased from 4,128.01 (Mar 24) to 4,724.36, marking an increase of 596.35.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.46 (Mar 24) to 1.30, marking a decrease of 0.16.
• For EV / EBITDA (X), as of Mar 25, the value is 9.16. This value is within the healthy range. It has decreased from 9.99 (Mar 24) to 9.16, marking a decrease of 0.83.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.17 (Mar 24) to 1.01, marking a decrease of 0.16.
• For Retention Ratios (%), as of Mar 25, the value is 78.91. This value exceeds the healthy maximum of 70. It has increased from 76.44 (Mar 24) to 78.91, marking an increase of 2.47.
• For Price / BV (X), as of Mar 25, the value is 3.93. This value exceeds the healthy maximum of 3. It has decreased from 4.18 (Mar 24) to 3.93, marking a decrease of 0.25.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.17 (Mar 24) to 1.01, marking a decrease of 0.16.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness